Management of Mucormycosis

AbstractPurpose of ReviewMucormycosis is an aggressive disease with high (>  30–50%) mortality. Many attempts have been made to improve the outcome including global consensus guideline to manage mucormycosis. In this review, we discuss various aspects of the current management strategies of mucormycosis.Recent FindingsNew global consensus guideline not only addressed the management issues in developed countries but also recommended algorithm in a resource-limiting environment. Isavuconazole, a new water-soluble triazole with good pharmacokinetics and safety profile, has emerged as a promising agent with anti-Mucorales activity. The drug can be used even as first-line therapy with a moderate recommendation. New antifungal agents including Manogepix (MGX), VT-1161, and statins with anti-Mucorales activity are undergoing clinical trials. Different routes of antifungal administration for targeted delivery are being explored, viz., nebulization, topical treatment, intravitreal route.SummaryEarly diagnosis and prompt therapy remain the cornerstone of mucormycosis management. Few recent studies reemphasized the need for combined management with surgical debridement of necrotic tissue, antifungal therapy, and reversal of underlying disease for a better outcome. New drug isavuconazole covers some of the gaps in management of patients with renal and hepatic compromise. Combination antifungal therapy remains controversial and requires prospective randomized studies. Adjuvant ther...
Source: Current Fungal Infection Reports - Category: Infectious Diseases Source Type: research